PRIMARY SJÖGREN'S SYNDROME · SECONDARY SJÖGREN'S · AUTOIMMUNE EXOCRINOPATHY
A physician-led, laboratory-verified treatment programme designed to modulate autoimmune activity, restore exocrine gland function and reduce systemic complications — tailored to the individual immunological profile, disease severity and organ involvement of each Sjögren's patient.
Request Medical ConsultationAbout the Condition
Sjögren's syndrome is a chronic systemic autoimmune disorder in which the immune system attacks the body's moisture-producing exocrine glands — primarily the salivary and lacrimal (tear) glands. This leads to persistent dryness of the eyes and mouth, but the disease frequently extends beyond glandular tissue to affect joints, lungs, kidneys and the nervous system.
The condition affects approximately 0.5–1% of the adult population, with a 9:1 female predominance. Diagnosis is often delayed by 5–7 years due to symptom overlap with other autoimmune conditions and the gradual onset of sicca (dryness) symptoms.
Current standard treatment relies on symptom management — artificial tears, saliva substitutes, hydroxychloroquine and immunosuppressants. These approaches do not address the underlying autoimmune destruction of glandular tissue, which is the central target of our cellular therapy programme.
Primary Sjögren's Syndrome
Occurs as a standalone autoimmune condition without association with other connective tissue diseases. Characterised by lymphocytic infiltration of salivary and lacrimal glands, anti-SSA/Ro and anti-SSB/La antibodies, and progressive glandular destruction. Affects approximately 50–60% of all Sjögren's patients.
Secondary Sjögren's Syndrome
Develops in association with another autoimmune disease — most commonly rheumatoid arthritis, systemic lupus erythematosus or systemic sclerosis. Sicca symptoms coexist with the clinical profile of the primary condition. Treatment must account for both disease processes simultaneously.
Sjögren's with Systemic Manifestations
Beyond glandular involvement, the disease affects internal organs — interstitial lung disease, renal tubular acidosis, peripheral neuropathy or CNS vasculitis. Requires close monitoring and a more aggressive immunomodulatory approach. Systemic involvement occurs in approximately 30–40% of patients.
Sjögren's with Lymphoproliferative Risk
Patients with persistent parotid gland enlargement, cryoglobulinaemia, low complement levels or monoclonal gammopathy carry an elevated risk of B-cell non-Hodgkin lymphoma — approximately 5–10% lifetime risk. These patients require ongoing haematological surveillance alongside immunomodulatory treatment.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, disease activity (ESSDAI), symptom burden (ESSPRI), serological markers and organ involvement.
We do not offer a cure for Sjögren's syndrome. Our programme targets the immunological mechanisms driving glandular destruction and systemic inflammation — with the clinical objective of restoring partial gland function, reducing disease activity and improving daily quality of life.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2017 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
24
Sjögren's syndrome patients treated
72%
demonstrated measurable improvement in at least one disease activity domain within 2–5 months
67%
showed objective improvement in salivary flow rate (unstimulated sialometry)
63%
reported clinically meaningful reduction in ocular and oral dryness
−3.8 pts
average ESSDAI score reduction at 5-month follow-up
58%
maintained sustained disease stabilisation — follow-up to 2 years
Improved unstimulated salivary flow rate
67%
Reduced Schirmer test deficit (tear production)
54%
Reduction in systemic fatigue severity (ESSPRI fatigue domain)
71%
Decreased joint pain and morning stiffness
58%
Stabilisation or improvement in pulmonary function markers
42%
2–6 weeks
Initial functional response
2–5 months
Clinically meaningful change
1–2 years under continued monitoring
Disease stabilisation phase
Important: Outcomes depend on Sjögren's subtype, baseline ESSDAI/ESSPRI scores, degree of glandular fibrosis, disease duration and individual biological response. Patients with advanced glandular atrophy may experience more limited improvement in salivary and lacrimal function. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“Eight years I couldn't eat without a glass of water next to my plate. After treatment my dentist measured actual saliva production for the first time in years. I stopped waking up with mouth sores every morning. The fatigue lifted enough that I went back to working full days, something I genuinely did not think would happen again.”
Patient
Primary Sjögren's syndrome · Italy
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our Sjögren's programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's immunological profile, glandular status, systemic involvement and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion or targeted local injection — not surgical instruments. No incisions, no gland removal.
No general anaesthesia
All procedures are performed under local anaesthesia or without anaesthesia at all. Important for patients on multiple immunosuppressive medications.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets the autoimmune mechanism, not just dryness symptoms
Rather than replacing moisture artificially, our protocol targets the lymphocytic infiltration, B-cell hyperactivity and immune dysregulation that destroy glandular tissue — the biological root of the disease.
Complements existing medication
Our programme is compatible with hydroxychloroquine, methotrexate, rituximab and other current medications. Patients do not need to discontinue existing treatment before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world. For patients with severe fatigue or systemic complications where travel is difficult, this removes a major barrier to accessing care.
What It Is
MSCs are multipotent regenerative cells with established immunomodulatory and tissue-protective properties. They have demonstrated efficacy in multiple autoimmune contexts and are among the most studied cell types in regenerative immunology.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Sjögren's Syndrome
In Sjögren's syndrome, chronic lymphocytic infiltration progressively destroys exocrine gland tissue. MSCs modulate this autoimmune process by suppressing pathogenic T-cell and B-cell activity within the glands, reducing local inflammation and creating conditions that allow surviving glandular cells to recover partial secretory function.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, disease activity scores, serological profile, glandular function status and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current ESSDAI/ESSPRI status, serological markers, organ involvement and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation — rheumatology reports, salivary gland biopsy, Schirmer test results, serological panel and imaging. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured rehabilitation sessions with our specialist, including glandular function exercises, ocular surface management protocols and systemic symptom tracking. Available at our clinic or remotely coordinated with your local rheumatology team.
Your dedicated coordinator monitors disease activity, glandular function and systemic status. Serological markers and ESSDAI/ESSPRI scores are tracked at defined intervals. A medical-grade wearable bracelet supports continuous health monitoring regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of Sjögren's syndrome patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and reflect normal immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed — including acute infection flare or new systemic involvement — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rheumatology-trained coordinator
monitors glandular function, systemic symptoms and serological markers
Personalised rehabilitation programme
including ocular surface protocols, salivary stimulation exercises and fatigue management
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in disease activity
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Autoimmune modulation is a gradual biological process. Glandular tissue that has been under immune attack for years does not recover in weeks. The post-treatment period requires structured monitoring, periodic reassessment and — where indicated — protocol adjustment based on evolving clinical data.
Get Started
If you or someone you love has been diagnosed with Sjögren's syndrome, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, disease activity and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
